Licensing Momentum Philogen already monetizes Nidlegy through Sun Pharma across Europe, Australia and New Zealand, with ongoing licensing and distribution deals, showing a proven path to market that can be replicated for additional regions or new angiogenesis assets.

Manufacturing Capacity GMP-certified expansion in Rosia (Siena) increases manufacturing capacity and quality controls, enabling contract or toll manufacturing and supply for late-stage trials or potential commercialization with partners.

Discovery Power Zurich-based Philochem serves as the in-house R&D engine, enabling rapid isolation and optimization of angiogenesis-targeting antibodies to support co-development or provide ready-to-advance candidates for partners.

Portfolio Focus A focused pipeline of anti-angiogenesis antibodies with multiple cancer derivatives and an RA candidate, plus upcoming registrational studies, offers partners vascular-targeted therapies for oncology and autoimmune indications.

Funding Credibility A history of funding rounds and collaborations with major pharma (Sun Pharma, plus relationships with Novartis, Celgene, Janssen) signals financial backing and deal-making credibility to accelerate new partnerships.